Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 217 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Difficile Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

NCT06258551
View directory record Official record
Conditions
Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

NCT02692651
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
Fidaxomicin, Vancomycin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

The Clostridioides Difficile Trial of REC-3964

NCT06536465
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection
Interventions
REC-3964
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 115 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Toms River, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 4 Interventional

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

NCT03880539
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
bezlotoxumab, Vancomycin Oral
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

NCT00384527
View directory record Official record
Conditions
Clostridium Infections
Interventions
Nitazoxanide, Vancomycin
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Torrance, California • Bay Pines, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 21, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

NCT07513285
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Ibezapolstat
Drug
Lead sponsor
Acurx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
19
States / cities
Sacramento, California • Hamden, Connecticut • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection

NCT03349268
View directory record Official record
Conditions
Healthcare Associated Infection, Clostridium Difficile Infection, Infection Due to Multidrug Resistant Bacteria
Interventions
Pulsed xenon ultraviolet (PX-UV) Device, Sham Device
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25,732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Enrolling by invitation Phase 1 Interventional

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

NCT01868373
View directory record Official record
Conditions
Active C. Difficile Colitis
Interventions
Microbiota Transplantation (FMT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 21, 2026, 9:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

NCT05606159
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Bacillus velezensis DSM 33864, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 21, 2026, 9:23 AM EDT
Completed No phase listed Observational

REBYOTA™ Prospective Registry

NCT05835219
View directory record Official record
Conditions
Recurrence of Clostridium Difficile Infection
Interventions
REBYOTA™
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Chula Vista, California • Murrieta, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Specific Carbohydrate Diet for Clostridium Difficile

NCT03925636
View directory record Official record
Conditions
Clostridium Difficile Infection, Diet Modification
Interventions
Specific Carbohydrate Diet
Dietary Supplement
Lead sponsor
David Suskind
Other
Eligibility
18 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

NCT02200328
View directory record Official record
Conditions
Clostridium Difficile Diarrhea
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Alison Schneider
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 21, 2026, 9:23 AM EDT
Terminated Phase 4 Interventional Results available

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

NCT00177970
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
intravenous immunoglobulin G (IVIG), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

NCT03589768
View directory record Official record
Conditions
Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation, Pertussis, Tetanus, Tetanus Immunisation
Interventions
Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 2 Interventional

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

NCT00772343
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile Infection
Interventions
0.9% Normal Saline, Clostridium difficile toxoid vaccine, Clostridium difficile toxoid vaccine with adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Tampa, Florida • Marietta, Georgia • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 21, 2026, 9:23 AM EDT
Completed No phase listed Observational

FQ Restriction for the Prevention of CDI

NCT03848689
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions
fluoroquinolone preprescription authorization, Control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
5,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

C. Difficile and Ursodiol

NCT02748616
View directory record Official record
Conditions
Diarrhea
Interventions
Ursodiol
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Withdrawn No phase listed Observational

Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

NCT04070352
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
Fidaxomicin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 21, 2026, 9:23 AM EDT
Enrolling by invitation Phase 1 Interventional

Fecal Microbiome Transplant

NCT02636517
View directory record Official record
Conditions
Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Judith Kelsen
Other
Eligibility
3 Years to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

NCT02053350
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 3 Interventional

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

NCT00106509
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
tolevamer potassium-sodium (GT267-004)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
99
States / cities
Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

NCT00130221
View directory record Official record
Conditions
Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions
2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap
Drug · Other
Lead sponsor
Cook County Health
Government
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

NCT03110133
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 21, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

NCT03462459
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
Interventions
Vancomycin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 21, 2026, 9:23 AM EDT